ArticleScience advances2022
Application of combined CRISPR screening for genetic and chemical-genetic interaction profiling in
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Deficiency of the Mycobacterial Lipoarabinomannan Biosynthesis Glycosyltransferase MptC Enhances Antibacterial Immune Response and Rifapicin Antibiotic Susceptibility.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability.Journal of pharmaceutical analysis · 2026Review
- Comprehensive Approaches to Protein Detection and Analysis in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Review
- A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference inACS infectious diseases · 2025Article
- The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses.Communications biology · 2025Article
- GrcC1 mediates low-level resistance to multiple drugs inMicrobiology spectrum · 2025Article
- Article
- Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.Microorganisms · 2025Review
- Lipid Trafficking in Diverse Bacteria.Accounts of chemical research · 2025Review
- Combining Oligo Pools and Golden Gate Cloning to Create Protein Variant Libraries or Guide RNA Libraries for CRISPR Applications.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Structure and function ofProceedings of the National Academy of Sciences of the United States of America · 2024Article
- CRISPR Screening and Comparative LC-MS Analysis Identify Genes Mediating Efficacy of Delamanid and Pretomanid against Mycobacterium tuberculosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The rise and future of CRISPR-based approaches for high-throughput genomics.FEMS microbiology reviews · 2024Review
- Blunted blades: new CRISPR-derived technologies to dissect microbial multi-drug resistance and biofilm formation.mSphere · 2024Review
- Application of CRISPR-cas-based technology for the identification of tuberculosis, drug discovery and vaccine development.Molecular biology reports · 2024Review
- Identification ofInfection and drug resistance · 2024Review
- Chemical approaches to unraveling the biology of mycobacteria.Cell chemical biology · 2023Review
- Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine.Frontiers in microbiology · 2023Review
- A CRISPR-Cas12a-based platform for ultrasensitive rapid highly specific detection ofFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR screening, including CRISPR interference (CRISPRi) and CRISPR-knockout (CRISPR-KO) screening, has become a powerful technology in the genetic screening of eukaryotes. In contrast with eukaryotes, CRISPR-KO screening has not yet been applied to functional genomics studies in bacteria. Here, we constructed genome-scale CRISPR-KO and also CRISPRi libraries in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.